Custom Antibody Service Global Market Report 2022: Advantages Across Wide Variety of Applications Fuels Adoption
November 30, 2022 08:23 ET | Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Custom Antibody Service Market, by Service Type, by Product Type, by Source, by Application, by End Users, and by Region - Size, Share, Outlook, and...
Dyadic Logo Current.jpg
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
November 10, 2022 16:00 ET | Dyadic International, Inc.
Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for...
The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030
November 08, 2022 06:28 ET | Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type, By Application, By End-Use, By Region,...
Dyadic Logo Current.jpg
Dyadic to Present at Upcoming Industry and Investor Events in November
November 07, 2022 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
$264 Worldwide Monoclonal Antibody Therapeutics Industry to 2027 - Featuring AbbVie, Amgen, Bayer and Biogen Among Others
November 01, 2022 05:28 ET | Research and Markets
Dublin, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Therapeutics Market (2022-2027) by Source, End-Users, Applications, and Geography, Competitive Analysis and the Impact of...
Dyadic Logo Current.jpg
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
October 27, 2022 16:30 ET | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
October 27, 2022 09:04 ET | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Global Research Antibodies Market Analysis Report 2022: A $2.21 Billion Market by 2030 - Expansion in Neurobiology and Stem Cell Research to Propel Growth
October 24, 2022 04:23 ET | Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Research Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), by Type, by Technology, by Source, by Application,...
Cancer Monoclonal Antibodies Market Report 2022: Featuring AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Merck & More
October 19, 2022 08:08 ET | Research and Markets
Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Intravenous Immunoglobulin Global Market Report 2022: Growing Pharmaceutical Industry Presents Opportunities
October 12, 2022 06:03 ET | Research and Markets
Dublin, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The "Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, Distribution Channel, End User, and...